Tolerability and Pharmacokinetics of Antofloxacin Hydrochloride after Multiple Oral Dose Administration in Healthy Chinese Male Volunteers.

Y. Xiao,Y. Lu,Z. Kang,F. Hou,S. Wang,T. Li,Y. Liu,Y. Xia
DOI: https://doi.org/10.5414/cpp46172
2008-01-01
International Journal of Clinical Pharmacology and Therapeutics
Abstract:Objective: To evaluate the tolerability and pharmacokinetics characteristics of antofloxacin hydrochloride, a fluoroquinolone developed in China, after multiple oral doses in healthy male Chinese volunteers. Methods: 13 subjects took 300 mg of antofloxacin hydrochloride once daily for 7 days. Safety was evaluated on Days 0, 2, 4 and 8. Blood and urine samples for pharmacokinetics analysis were taken at designated time points. HPLC was used to assay the serum and urine concentration of antofloxacin. Results: A total of 12 subjects completed the trial and 1 volunteer was dropped because of a skin rash 2 h after the drug was administered. 1 volunteer had a prolonged prothrombin time (PT), another had a serum alanine aminotransferase (ALT) elevation and a third had increases in aspartate aminotransferase (AST) and gamma-glutamyltransferase (gamma-GT). No other complaints were reported during the trial. The steady state serum concentration on a daily 300 mg oral dose was obtained at 96 h. The pharmacokinetics parameters at steady state were: t(max) 1.19 +/- 0.59 h, C-max 4.49 +/- 0.81 mg/1, C-min 1.35 +/- 0.33 mg/1, AUC(ss) 74.74 +/- 12.58 mg/1 x h, C-av 3.11 +/- 0.52 mg/1, t(1/2 beta) 20.75 +/- 2.93 h, PTF 102.13 +/- 23.92%. The urinary elimination of antofloxacin over 120 h after the last dose was approximately 62%. C-max in steady state was 50% higher compared to data for Day 1 after a single dose administration. Conclusions: The results indicated that 300 mg antofloxacin hydrochloride once daily oral administration is safe, but can lead to high drug concentrations. This should be evaluated further.
What problem does this paper attempt to address?